A five‑gene based risk score with high prognostic value in colorectal cancer
Open Access
- 28 September 2017
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (6) , 6724-6734
Abstract
Colorectal cancer (CRC) is one of the most frequently occurring malignancies worldwide. The outcomes of patients with similar clinical symptoms or at similar pathological stages remain unpredictable. This inherent clinical diversity is most likely due to the genetic heterogeneity. The present study aimed to create a predicting tool to evaluate patient survival based on genetic profile. Firstly, three Gene Expression Omnibus (GEO) datasets (GSE9348, GSE44076 and GSE44861) were utilized to identify and validate differentially expressed genes (DEGs) in CRC. The GSE14333 dataset containing survival information was then introduced in order to screen and verify prognosis‑associated genes. Of the 66 DEGs, the present study screened out 46 biomarkers closely associated to patient overall survival. By Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analysis, it was demonstrated that these genes participated in multiple biological processes which were highly associated with cancer proliferation, drug‑resistance and metastasis, thus further affecting patient survival. The five most important genes, MET proto‑oncogene, receptor tyrosine kinase, carboxypeptidase M, serine hydroxymethyltransferase 2, guanylate cyclase activator 2B and sodium voltage‑gated channel a subunit 9 were selected by a random survival forests algorithm, and were further made up to a linear risk score formula by multivariable cox regression. Finally, the present study tested and verified this risk score within three independent GEO datasets (GSE14333, GSE17536 and GSE29621), and observed that patients with a high risk score had a lower overall survival (P<0.05). Furthermore, this risk score was the most significant compared with other predicting factors including age and American Joint Committee on Cancer stage, in the model, and was able to predict patient survival independently and directly. The findings suggest that this survival associated DEGs‑based risk score is a powerful and accurate prognostic tool and is promisingly implemented in a clinical setting.Keywords
This publication has 38 references indexed in Scilit:
- SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearanceNature, 2015
- Improved survival among colon cancer patients with increased differentially expressed pathwaysBMC Medicine, 2015
- Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patientsHuman Genome Variation, 2015
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft ModelMedical Science Monitor, 2015
- Gene Expression Profiles Accurately Predict Outcome Following Liver Resection in Patients with Metastatic Colorectal CancerPLOS ONE, 2013
- Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinomaGut, 2013
- The potential of carboxypeptidase M as a therapeutic target in cancerExpert Opinion on Therapeutic Targets, 2013
- GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomicsNucleic Acids Research, 2012
- Prediction of Colorectal Cancer Risk Using a Genetic Risk Score: The Korean Cancer Prevention Study-II (KCPS-II)Genomics & Informatics, 2012